Iron­wood looks to boost gout fran­chise as FDA de­liv­ers OK for Duza­l­lo

Iron­wood Phar­ma­ceu­ti­cals $IR­WD is on track to boost­ing its gout drug fran­chise with the launch of Duza­l­lo, a com­bo ther­a­py that match­es lesin­u­rad and al­lop­uri­nol in one pill.

The Cam­bridge, MA-based biotech likes to at­tach its own peak sales es­ti­mates to the prod­ucts it de­vel­ops. And CEO Pe­ter Hecht has made it clear that this com­bo ther­a­py — match­ing two ap­proach­es to hy­pe­r­uricemia (the over­pro­duc­tion and un­der­ex­cre­tion of serum uric acid) — will dri­ve the biotech’s fran­chise for un­con­trolled gout to $300 mil­lion-plus in an­nu­al sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER